Moris Dimitrios, Ronnekleiv-Kelly Sean, Kostakis Ioannis D, Tsilimigras Diamantis I, Beal Eliza W, Papalampros Alexandros, Dimitroulis Dimitrios, Felekouras Evangelos, Pawlik Timothy M
Department of Surgery, Division of Surgical Oncology, Wexner Medical Center and James Cancer Hospital and Solove Research Institute, The Ohio State University, 395 W. 12th Ave., Suite 670, Columbus, OH, USA.
Department of Surgery, Division of Surgical Oncology, Johns Hopkins Hospital, Baltimore, MD, USA.
World J Surg. 2018 Mar;42(3):806-815. doi: 10.1007/s00268-017-4181-6.
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has recently emerged as a treatment choice for patients with colorectal liver metastases (CLM) and inadequate future liver remnant (FLR). The aim of this study was to define the results of ALPPS compared with two-stage hepatectomy (TSH) for patients with CLM.
A meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines. Identification of eligible studies was performed using three distinct databases through February 2017; Medline, ClinicalTrials.gov and Cochrane library-Cochrane Central Register of Controlled Trials using a syntax including medical subject headings terms "portal vein ligation," "PVE," "staged hepatectomy," "staged liver resection," "liver resection," "two-stage hepatectomy," "TSH," "in situ liver transection with portal vein ligation," "associating liver partition and portal vein ligation for staged hepatectomy" and "ALPPS".
Among the 634 records identified, 9 studies comparing ALPPS with TSH met the inclusion criteria. These studies included 657 patients with unresectable CLM (ALPPS, n = 186 vs TSH, n = 471). There was no difference in final postoperative FLR between ALPPS versus TSH (mean difference: 31.72, 95% CI: -27.33 to 90.77, p = 0.29). The kinetic growth rate was faster with the ALPPS versus TSH (mean difference 19.07 ml/day, 95% CI 8.12-30.02, p = 0.0006). TSH had a lower overall and major morbidity versus ALPPS (overall morbidity: RR: 1.39, 95% CI: 1.07-1.8, p = 0.01; I : 58%, p = 0.01; major morbidity: RR: 1.57, 95% CI: 1.18-2.08, p = 0.002; I : 0%, p = 0.44). Overall survival was comparable following ALPPS versus TSH.
While ALPPS may be a suitable approach for patients, the higher morbidity and mortality should be considered when determining the operative approach for patients with extensive CLM.
联合肝脏分隔和门静脉结扎的分期肝切除术(ALPPS)最近已成为治疗结直肠癌肝转移(CLM)且未来肝脏剩余体积(FLR)不足患者的一种治疗选择。本研究的目的是明确ALPPS与两阶段肝切除术(TSH)治疗CLM患者的效果。
根据系统评价和Meta分析的首选报告项目指南进行Meta分析。通过三个不同的数据库检索截至2017年2月符合条件的研究;使用包括医学主题词“门静脉结扎”“门静脉栓塞”“分期肝切除术”“分期肝切除”“肝切除”“两阶段肝切除术”“TSH”“门静脉结扎原位肝离断”“联合肝脏分隔和门静脉结扎的分期肝切除术”和“ALPPS”的语法在Medline、ClinicalTrials.gov和Cochrane图书馆 - Cochrane对照试验中央注册库中进行检索。
在检索到的634条记录中,9项比较ALPPS与TSH的研究符合纳入标准。这些研究纳入了657例不可切除CLM患者(ALPPS组186例,TSH组471例)。ALPPS组与TSH组术后最终FLR无差异(平均差异:31.72,95%可信区间:-27.33至90.77,p = 0.29)。ALPPS组的肝脏体积增长速率比TSH组更快(平均差异19.07ml/天,95%可信区间8.12 - 30.02,p = 0.0006)。TSH组的总体和严重并发症发生率低于ALPPS组(总体并发症发生率:RR:1.39,95%可信区间:1.07 - 1.8,p = 0.01;I²:58%,p = 0.01;严重并发症发生率:RR:1.57,95%可信区间:1.18 - 2.08,p = 0.002;I²:0%,p = 0.44)。ALPPS组与TSH组的总生存率相当。
虽然ALPPS可能是适合患者的一种方法,但在为广泛CLM患者确定手术方式时应考虑其较高的发病率和死亡率。